Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more ...
Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...
One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...
Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.
Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use. PharmaJet injector pens are intended for needle-free subcutaneous delivery of a ...
Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after ...
Patent expiry sets off fresh competition as weight loss drugs spill into advertising, awareness campaigns and influencer conversations.
Within England's National Health Service (NHS), switching from disposable insulin pens to reusable insulin cartridge pens would be either cost-neutral or cost-saving and would reduce plastic waste by ...
The presenters will also highlight the unmet need and market opportunity driving PharmaJet’s expansion into the self-injection pen market. Dr. Wouter Latour, CEO of PharmaJet, will present Reusable ...
Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.
The global pen needles market is projected to grow at a robust CAGR of 9% over the next five years. This growth is primarily driven by the rising prevalence of diabetes and other chronic conditions, ...
Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results